Cargando…
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...
Autores principales: | Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312923/ https://www.ncbi.nlm.nih.gov/pubmed/25080865 http://dx.doi.org/10.1002/ijc.29113 |
Ejemplares similares
-
Systemic antibiotic therapy as an adjunct to non‐surgical peri‐implantitis treatment: A single‐blind RCT
por: De Waal, Yvonne C. M., et al.
Publicado: (2021) -
The effect of omega‐3 fatty acids on active periodontal therapy: A systematic review and meta‐analysis
por: Van Ravensteijn, Myrlon M., et al.
Publicado: (2022) -
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated
with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012) -
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022) -
Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)